Cytokines and Inflammatory Bowel Disease

Chapter
First Online:

Abstract

The etiology of inflammatory bowel diseases (IBD) is generally described as multifactorial including genetic predisposition, environmental insult, and a dysregulated immune response. The immune response is the only one of these that is currently amenable to therapy. Understanding the factors that go into the activation of the inflammation, and those that perpetuate this effect is improving greatly. With this mastery we are able to define the cytokines that are important in the etiology of IBD. Over the past 15 years, many of the newest and arguably the most successful therapies for Crohn disease (CD) and ulcerative colitis (UC) have been due to an increased understanding of the immune response and specifically the cytokines essential to this response.

As stated earlier, IBD is in part due to a dysregulated or an inappropriate immune reaction, which has been thought in part to be against to the microflora of the gut. Upon activation of the immune system, cytokines and chemokines, which are proteins produced by the cells involved in the immune response, are produced, and trigger a cascade of downstream reactions. These cytokines are increasingly being defined as important molecules in the pathogenesis of IBD as well as putative and known targets for the therapy of IBD.

Keywords

Inflammatory Bowel Disease Ulcerative Colitis Treg Cell Regulatory Cell Inflammatory Bowel Disease Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Neurath MF, et al. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med. 1996;183(6):2605–16.PubMedCrossRefGoogle Scholar
  2. 2.
    Reinecker HC, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol. 1993;94(1):174–81.PubMedCrossRefGoogle Scholar
  3. 3.
    Camoglio L, et al. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis. 1998;4(4):285–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Boirivant M, et al. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med. 1998;188(10):1929–39.PubMedCrossRefGoogle Scholar
  5. 5.
    Shetty A, Forbes A. Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn’s disease. Am J Pharmacogenomics. 2002;2(4):215–21.PubMedCrossRefGoogle Scholar
  6. 6.
    Strober W, et al. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol Today. 1997;18(2):61–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Neurath MF, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol. 1997;27(7):1743–50.PubMedCrossRefGoogle Scholar
  8. 8.
    Murch SH, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991;32(8):913–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Reimund JM, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn’s disease. J Clin Immunol. 1996;16(3):144–50.PubMedCrossRefGoogle Scholar
  10. 10.
    Targan SR, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–35.PubMedCrossRefGoogle Scholar
  11. 11.
    Hanauer SB, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Colgan SP, et al. Interferon-gamma induces a cell surface phenotype switch on T84 intestinal epithelial cells. Am J Physiol. 1994;267(2 Pt 1):C402–10.PubMedGoogle Scholar
  13. 13.
    Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495–549.PubMedCrossRefGoogle Scholar
  14. 14.
    Reinisch W, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn’s disease. Gut. 2006;55(8):1138–44.PubMedCrossRefGoogle Scholar
  15. 15.
    Hommes DW, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease. Gut. 2006;55(8):1131–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Cominelli F, Pizarro TT. Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease. Aliment Pharmacol Ther. 1996;10(Suppl 2):49–53; discussion 54.Google Scholar
  17. 17.
    Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn’s disease. Gut. 1989;30(6):835–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Andus T, et al. Imbalance of the interleukin 1 system in colonic mucosa—association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2. Gut. 1997;41(5):651–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Van Assche G, et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol. 2003;98(2):369–76.PubMedCrossRefGoogle Scholar
  20. 20.
    Van Assche G, et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut. 2006;55(11):1568–74.PubMedCrossRefGoogle Scholar
  21. 21.
    Cantor MJ, Nickerson P, Bernstein CN. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am J Gastroenterol. 2005;100(5):1134–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol. 2005;28(3):187–96.PubMedCrossRefGoogle Scholar
  23. 23.
    Ito H, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology. 2004;126(4):989-96; discussion 947.Google Scholar
  24. 24.
    Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3(7):521–33.PubMedCrossRefGoogle Scholar
  25. 25.
    Fuss IJ, et al. Both IL-12p70 and IL-23 are synthesized during active Crohn’s disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis. 2006;12(1):9–15.PubMedCrossRefGoogle Scholar
  26. 26.
    Mannon PJ, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med. 2004;351(20):2069–79.PubMedCrossRefGoogle Scholar
  27. 27.
    Fuss IJ, et al. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology. 1999;117(5):1078–88.PubMedCrossRefGoogle Scholar
  28. 28.
    Harrington LE, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123–32.PubMedCrossRefGoogle Scholar
  29. 29.
    Hue S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med. 2006;203(11):2473–83.PubMedCrossRefGoogle Scholar
  30. 30.
    Fujino S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65–70.PubMedCrossRefGoogle Scholar
  31. 31.
    Langrish CL, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201(2):233–40.PubMedCrossRefGoogle Scholar
  32. 32.
    Kullberg MC, et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med. 2006;203(11):2485–94.PubMedCrossRefGoogle Scholar
  33. 33.
    Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity. 2004;21(4):467–76.PubMedCrossRefGoogle Scholar
  34. 34.
    Mangan PR, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006;441(7090):231–4.PubMedCrossRefGoogle Scholar
  35. 35.
    Bettelli E, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Ahern PP, et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity. 2010;33(2):279–88.PubMedCrossRefGoogle Scholar
  37. 37.
    Sujino T, et al. Regulatory T cells suppress development of colitis, blocking differentiation of T-helper 17 into alternative T-helper 1 cells. Gastroenterology. 2011;141(3):1014–23.PubMedCrossRefGoogle Scholar
  38. 38.
    Duerr RH, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314(5804):1461–3.PubMedCrossRefGoogle Scholar
  39. 39.
    Wang K, et al. Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. Am J Hum Genet. 2009;84(3):399–405.PubMedCrossRefGoogle Scholar
  40. 40.
    Pizarro TT, et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn’s disease: expression and localization in intestinal mucosal cells. J Immunol. 1999;162(11):6829–35.PubMedGoogle Scholar
  41. 41.
    Reuter BK, Pizarro TT. Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe? Eur J Immunol. 2004;34(9):2347–55.PubMedCrossRefGoogle Scholar
  42. 42.
    Okamura H, et al. Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol. 1998;10(3):259–64.PubMedCrossRefGoogle Scholar
  43. 43.
    Nakanishi K, et al. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001;12(1):53–72.PubMedCrossRefGoogle Scholar
  44. 44.
    Fuss IJ, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004;113(10):1490–7.PubMedGoogle Scholar
  45. 45.
    Heller F, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129(2):550–64.PubMedGoogle Scholar
  46. 46.
    Schiechl G, et al. Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. J Clin Invest. 2011;121(5):1692–708.PubMedCrossRefGoogle Scholar
  47. 47.
    Prehn JL, et al. The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol. 2007;178(7):4033–8.PubMedGoogle Scholar
  48. 48.
    Takedatsu H, et al. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology. 2008;135(2):552–67.PubMedCrossRefGoogle Scholar
  49. 49.
    Meylan F, et al. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity. 2008;29(1):79–89.PubMedCrossRefGoogle Scholar
  50. 50.
    Schreiber TH, et al. Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation. J Clin Invest. 2010;120(10):3629–40.PubMedCrossRefGoogle Scholar
  51. 51.
    Kamada N, et al. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn’s disease. Inflamm Bowel Dis. 2010;16(4):568–75.PubMedGoogle Scholar
  52. 52.
    Michelsen KS, et al. IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein. PLoS One. 2009;4(3):e4719.PubMedCrossRefGoogle Scholar
  53. 53.
    McClane SJ, Rombeau JL. Cytokines and inflammatory bowel disease: a review. JPEN J Parenter Enteral Nutr. 1999;23(5 Suppl):S20–4.PubMedCrossRefGoogle Scholar
  54. 54.
    Powrie F, et al. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med. 1996;183(6):2669–74.PubMedCrossRefGoogle Scholar
  55. 55.
    Maul J, et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 2005;128(7):1868–78.PubMedCrossRefGoogle Scholar
  56. 56.
    Bamias G, et al. Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology. 2005;128(3):654–66.PubMedCrossRefGoogle Scholar
  57. 57.
    Dohi T, et al. T helper type-2 cells induce ileal villus atrophy, goblet cell metaplasia, and wasting disease in T cell-deficient mice. Gastroenterology. 2003;124(3):672–82.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Pediatric IBD Center, Childrens Hospital ColoradoDigestive Health Institute, Anschutz Medical CampusDenverUSA
  2. 2.Mucosal Immunity Section, National Institutes of HealthNational Institute of Allergy Immunology and infectious DiseaseBethesdaUSA

Personalised recommendations